Back to results
US 12,589,159 B2Granted
CD71 binding fibronectin type III domains
AssigneeARO Biotherapeutics Company
InventorsRussell C. Addis, Zhanna Druzina, Robert Kolakowski, Swapnil Kulkarni, Steven G. Nadler, Karyn O'Neil, Yao Xin
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
Claims18
A method of delivering a polynucleotide to a muscle cell, wherein
- the method comprises contacting the muscle cell with the polynucleotide conjugated to a polypeptide that binds to cluster of differentiation 71 (CD71) and comprises the amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:
- 146.
Dependencies are inferred from the claim text.